Monopar Therapeutics Inc. announced on December 5, 2024, that the first patient has been dosed with its novel therapeutic radiopharmaceutical, MNPR-101-Lu. This treatment combines Monopar’s MNPR-101 antibody, which targets the urokinase plasminogen activator receptor (uPAR), with the therapeutic radioisotope lutetium-177.
The patient, suffering from metastatic pancreatic cancer, received the MNPR-101-Lu intravenous infusion under a compassionate use protocol in the US, and the infusion was well-tolerated with no serious adverse reactions reported. Prior imaging with MNPR-101-Zr confirmed uPAR expression in the cancer.
This event marks a significant advancement in Monopar's radiopharmaceutical program, building on encouraging biodistribution and dosimetry clinical data previously reported for MNPR-101-Zr. Monopar is also actively enrolling participants in two Phase 1 clinical studies in Australia for MNPR-101-Zr and MNPR-101-Lu.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.